Akari Therapeutics, Plc Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period
Akari Therapeutics, Plc (AKTX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period of 137.30 thousand shares for the 12-month period ending 2013-12-31, per its 10-K filed 2015-02-11.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod · last filed 2015-02-11
- Akari Therapeutics, Plc share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2013 was 137.30K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 12 month |
|---|---|
| 2013-12-31 | 137.30K shares 10-K · filed 2015-02-11 |
| 2011-12-31 | 15.00K shares 20-F/A · filed 2013-04-19 |
| 2008-12-31 | 285.00K shares 20-F/A · filed 2013-04-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ELI LILLY & Co (LLY) | United States | $1,113.804B | 42.28 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |